Association between the availability of medical oncologists and initiation of chemotherapy for patients with stage III colon cancer

Journal of Oncology Practice

Volumn 9, Issue 1, 2013, Pages 27-33

  Lin, Chun Chieh Anna ^a   Virgo, Katherine S ^b  

^a AMERICAN CANCER SOCIETY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARMUSTINE; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COLON CANCER; COLON RESECTION; FEMALE; HEALTH CARE AVAILABILITY; HEALTH MAINTENANCE ORGANIZATION; HOSPITAL CARE; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ONCOLOGIST; MEDICARE; NEIGHBORHOOD; PHYSICIAN;

AGED; AGED, 80 AND OVER; COLECTOMY; COLONIC NEOPLASMS; FEMALE; HOSPITALS; HUMANS; MALE; MEDICAL ONCOLOGY; MEDICARE; NEOPLASM STAGING; UNITED STATES;

EID: 84877789145     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000627     Document Type: Article

References (27)

1. Sundararajan V, Mitra N, Jacobson J, et al: Survival associated with 5-fluorouracil- based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136: 349-357, 2002
2. Iwashyna T, Lamont E: Effectiveness of adjuvant fluorouracil in clinical practice: A population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20: 3992-3998, 2002
3. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer. JAMA 294: 2703-2711, 2005
4. Zuckerman IH, Rapp T, Onukwugha E, et al: Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 57: 1403-1410, 2009
5. Sargent D, Goldberg R, Jacobson S, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097, 2001
6. Etzioni DA, El-Khoueiry AB, Beart RW Jr: Rates and predictors of chemotherapy use for stage III colon cancer. Cancer 113: 3279-3289, 2008
7. Sundararajan V, Grann VR, Jacobson JS, et al: Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population- based study. Cancer J 7: 213-218, 2001
8. Mahoney T, Kuo YH, Topilow A, et al: Stage III colon cancers: Why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135: 182-185, 2000
9. Baldwin LM, Dobie SA, Billingsley K, et al: Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97:1211- 1220, 2005
10. Schrag D, Cramer L, Bach P, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93: 850-857, 2001
11. Cronin D, Harlan L, Potosky A, et al: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol 101: 2308-2318, 2006
12. White A, Liu CC, Xia R, et al: Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002. Cancer 113: 3400-3409, 2008
13. Luo R, Giordano SH, Freeman JL, et al: Referral to medical oncology: A crucial step in the treatment of older patients with stage III colon cancer. Oncologist 11: 1025-1033, 2006
14. McGory M, Zingmond DS, Sekeris E, et al: A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum 49: 319-329, 2006
15. VanEenwyk J, Campo JS, Ossiander EM: Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. Cancer 95: 39-46, 2002
16. Li X, Butts C, Fenton D, et al: Utilization of oncology services and receipt of treatment: A comparison between patients with breast, colon, rectal, or lung cancer. Ann Oncol 22: 1902-1909, 2011
17. Neugut AI, Grann VR: Referral to medical oncologists: Are there barriers at the gate? J Clin Oncol 20: 1716-1718, 2002
18. Earle CC, Neumann PJ, Gelber RD, et al: Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 20: 1786-1792, 2002
19. Status of the medical oncology workforce: The American Society of Clinical Oncology. J Clin Oncol 14: 2612-2621, 1996
20. Davidoff AJ, Rapp T, Onukwugha E, et al: Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: The role of the medical oncologist evaluation. Med Care 47: 1229-1236, 2009
21. Onega T, Duell EJ, Shi X, et al: Geographic access to cancer care in the U.S. Cancer 112: 909-918, 2008
22. Dartmouth Atlas of Health Care. http://www.dartmouthatlas.org/tools/ downloads.aspx
23. Koroukian SM, Dahman B, Copeland G, et al: The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: A validation study. Health Serv Res 45: 265-282, 2010
24. Hu CY, Delclos G, Chan W, et al: Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol 28: 1062-1074, 2011
25. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450, 1990
26. Des Guetz G, Uzzan B, Morere JF, et al: Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev 1:CD007046, 2010
27. Erikson C, Salsberg E, Forte G, et al: Future supply and demand for oncologists: Challenges to assuring access to oncology services. J Oncol Pract 3:79- 86, 2007